clinical trial · NCT03254667
LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
Bausch Health Americas, Inc.·—·enrolling by invitation·n = 3,500
PsoriasisBrodalumabComparator Drug (non-biologic IL-17 inhibitors)
brief summary
Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis
started
Jul 25, 2017
primary completion
Nov 10, 2030
completion
Nov 1, 2031
last updated
Sep 16, 2025
detailed description
Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care
official title
Prospective, Observational Study Brodalumab Compared With Other Therapies in the Treatment of Adults With Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol